Non-invasive Brain Stimulation on Functional Capacity in Prefrail Older Adults (NCT07346989) | Clinical Trial Compass
RecruitingNot Applicable
Non-invasive Brain Stimulation on Functional Capacity in Prefrail Older Adults
Spain120 participantsStarted 2026-01-15
Plain-language summary
The general objective of this study is to evaluate the effectiveness of non-invasive neuromodulation combined with a therapeutic exercise program on neuroplasticity and, therefore, on variables related to functional capacity and quality of life, in prefrail older adults.
Who can participate
Age range
65 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 65 -90 years old
* Meet 1-2 frailty criteria, according to Fried's Criteria.
* Ability to understand instructions (Mini-Mental State Examination \>23 points).
* Signing of the informed consent.
Exclusion Criteria:
* History of stroke within the past 6 months or hospital admission for any reason within the past 3 months.
* Alterations of the central or peripheral nervous system
* Alterations of the vestibular system
* Concomitant diseases
* Have a neurological pathology, cardiovascular musculoskeletal that contraindicates physical activity
* Epilepsy or history, medications that lower the seizure threshold
* Cardiac pacemaker, endocranial and hearing implants
* History of severe headaches
* Uncontrolled intracranial or arterial hypertension
* Heart and/or respiratory failure
* Implanted medication pump
* Skin lesions (psoriasis, eczema)
* Serious head surgeries
* Completing less than 80% of training sessions
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Frailty Condition
Timeframe: Five assessments: Baseline (T1); After the first session, at Day 1 (T2); Mid-term assessment, 4 weeks after the intervention starts (T3); After the intervention, 8 weeks (T4); Four weeks after the end of the intervention (follow-up assessment) (T5).
2
Walking speed
Timeframe: Five assessments: Baseline (T1); After the first session, at Day 1 (T2); Mid-term assessment, 4 weeks after the intervention starts (T3); After the intervention, 8 weeks (T4); Four weeks after the end of the intervention (follow-up assessment) (T5).